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Abstract The MPTP metabolic activity of porcine FAD-con- 
taining monooxygenase (FMO) (EC 1.14.13.8) was inhibited con- 
siderably by deprenyl and pargyline, selective MAO-B inhibitors, 
and they showed typical competitive inhibition. Deprenyl and par- 
gyline, amine derivatives were also examined as to whether they 
are substrates for the FMO. It was found that deprenyl and par- 
gyline are excellent substrates for the FMO. The K i and K m values 
of deprenyl and pargyline for the FMO are 14 pM and 9 pM, 
and 14.3 pM and 11.6 pM, at pH 8.0 and 25°C, respectively. 
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[6]. The optical spectra of FMO are shown in Fig. 1, and the purified 
FMO gave a single protein band on SDS-PAGE (Fig. 2). 
2.3. Enzyme assay and kinetic parameters 
The enzymatic activity was determined optically and aerobically by 
measuring the decrease in absorbance at 340 nm due to the oxidation 
of NADPH in the presence of a substrate. The reaction mixture com- 
prised FMO (0.2 nmol), 0.1 M K-phosphate buffer, pH 8.0, at 25°C, 
and appropriate amounts of NADPH and 10 ~M to 600 ¢tM substrate, 
in a final volume of 1 ml. The reaction mixture was put into a cuvette 
of 1 cm light path and then the endogenous rate of the absorbance 
change at 340 nm was recorded for 5 rain at 25°C before addition of 
the substrate. After the addition of the substrate, the rate of the absorb- 
ance change was measured for 5 rain at 25°C, the endogenous rate being 
subtracted. For investigation of a reaction with a sequential Bi Bi 
mechanism, the Km, Vmax and K~ values of FMO for deprenyl and 
pargyline can be determined by means of Lineweaver-Burk plots [9]. 
1. Introduction 
It is well known that 1-methyl-4-phenyl-l,2,3,6-tetrahy- 
dropyridine (MPTP) neurotoxicity effectively produces Parkin- 
son's disease and Parkinsonism in humans, monkeys and mice 
[1,2], and it is believed that MPTP is only metabolized by 
monoamine oxidase-B (MAO-B) [3,4], because deprenyl and 
pargyline are selective and the only specific MAO-B inhibitors, 
and MPTP-metabolic activity was inhibited by these inhibitors 
[3]. However, we have reported that MPTP is also metabolized 
by FMO [5,6]. In addition, it has been reported that MPTP is 
metabolized by microsomal cytochromes P-450IA 1, P-450IIB 1 
and P-450IID6 [7]. 
In this study, we demonstrated that deprenyl and pargyline 
were not only strong inhibitors of the activity of  FMO toward 
MPTP, but also excellent substrates for FMO. The kinetic 
parameters for the inhibitors of FMO were determined. 
2. Materials and methods 
2.1. Materials 
Livers from female pigs (Landrace, 1-year-old) were obtained within 
1 h of sacrifice from a local slaughterhouse and transported immedi- 
ately to the laboratory on cracked ice. 
2.2. Preparation of liver microsomes and purification of FMO 
Fresh and healthy porcine livers were perfused carefully with an 
ice-cold 0.15 M KC1 solution (adjusted to pH 7.4 with 0.5 M Tris) to 
remove as much blood as possible at 0°C to 4°C. The liver microsomes 
were prepared by the method of Mitoma et al. [8]. FMO was purified 
from the porcine liver microsomes by the method of Wu and Ichikawa 
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2.4. Other analytical methods 
Protein was measured by means of the bicinchoninic acid method [10] 
or the biuret reaction [11], using bovine serum albumin as a standard 
marker protein. The concentration of FMO was determined using a 
molar extinction coefficient at 382 nm of 9.8 × 103 M -~ .cm -1 in 10 mM 
K-phosphate buffer (pH 7.4) containing 20% (V/V) glycerol, 0.1% (V/V) 
Triton X-100 and 1 mM EDTA, at 25°C [6]. The albumin content was 
determined optically using a molar extinction coefficient of 6.67 × 103 
M -1 -cm -~ at 280 nm [12]. The molar extinction coefficient at 340 nm 
of NADPH was taken to be 6.30 × 103 M -~ .cm -~ in 0.1 M K-phosphate 
buffer, pH 7.4 (25°C) [13]. 
2.5. Instruments 
Optical determinations were performed with a Hitachi double beam 
spectrophotometer, Model 557, equipped with a thermostatically con- 
trolled cell holder at 25°C. 
2.6. Chemicals 
R(-)-Deprenyl HC1 was obtained from Research Biochemicals In- 
corporated (USA), and pargyline HC1 and MPTP were purchased from 
Sigma Chemical Co. (St. Louis, MO). NADPH was purchased from 
Oriental Yeast Co. (Tokyo, Japan). The reagent solutions were pre- 
pared just before use to prevent decomposition. All other chemicals 
were of the highest grade commercially available. 
3. Results 
We purified FMO from porcine liver microsomes, and it gave 
a single protein band, and thus was very pure, on SDS-PAGE. 
The FMO was used for the experiments. The specific activity 
toward MPTP of the FMO was 6.2 nmol/min/nmol FMO at pH 
8.0 and 25°C. 
The effects of deprenyl and pargyline on the MPTP-oxida- 
tion activity of the FMO were examined kinetically by means 
of L ineweave~Burk plots. 
Figs. 3 and 4 show plots of the reciprocals of the MPTP 
concentrations against he reciprocals of the reaction velocities 
in the absence and presence of deprenyl or pargyline. The 
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Fig. 1. Absolute optical absorption spectra of the FMO in the oxidized 
and sodium dithionite-reduced forms. The cuvette contained 1.38 mg 
protein/ml in 10 mM K- phosphate buffer (pH 7.4) containing 20% (v/v) 
glycerol, 0.1% (v/v) Triton X-100 and 1 mM EDTA, at 25 ° C. The 
magnified spectra in the visible region were recorded at 2.5-fold greater 
sensitivity. Solid lines, oxidized form; broken line, sodium dithionite- 
reduced form; dotted lines, baseline. 
figures show typical competitive inhibition, and the Ki values 
are summarized in Table 1. 
Deprenyl and pargyline are amine derivatives, and they are 
excellent substrates for the FMO. 
The Km and Vm,x values for deprenyl and pargyline of the 
FMO were determined from reciprocal plots of the initial oxi- 
dative activities toward the substrates with various concentra- 
tions, from 25 to 100 pM, of NADPH against a series of fixed 
concentrations of deprenyl or pargyline. Figs. 5 and 6 show 
double reciprocal plots of the initial velocity of the FMO reac- 
tion with various concentrations of deprenyl or pargyline 
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Fig. 2. Electrophoretic pattern of the FMO on SDS-PAGE. 3.5 pg of 
FMO protein was subjected to SDS-PAGE using 10% (w/v) acrylamide. 
(1) FMO, (2) standard proteins. 
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Fig. 3. Effect of deprenyl on the activity of FMO toward MPTP. 
Double reciprocal plots of the initial reaction velocity of FMO against 
MPTP concentrations with a series of fixed concentrations of deprenyl. 
The enzymatic assays performed as described in section 2. Open circles, 
80/JM deprenyl; closed triangles, 40 pM deprenyl; open squares, with- 
out deprenyl. 
against a series of fixed concentrations of NADPH, respec- 
tively. The Km and Vmax values for deprenyl or pargyline of the 
FMO are also summarized in Table 1. 
4. Discussion 
Parkinson's disease and Parkinsonism are neurodegenerative 
disorders characterized clinically by rigidity and tremor, and 
pathologically by neuronal cell death in the substantia nigra of 
the brain [14]. The cause of the dopaminergic cell death that 
underlies Parkinson's disease remains obscure. However, the 
discovery that MPTP can induce Parkinson's disease and Park- 
insonism in humans has provided an important insight into the 
causes of idiopathic Parkinson's disease and Parkinsonism [2]. 
It has been believed that the toxicity of MPTP toward dopam- 
inegic neurons is dependent on the metabolism of MPTP by 
only glial MAO-B [15], because selective inhibitors, deprenyl 
and pargyline, of MAO-B completely inhibited the metabolism 
of MPTP, and these inhibitors did not inhibit other enzymes 
[3,4]. 
In this study, we demonstrated that deprenyl and pargyline, 
which are recognized to be selective MAO-B inhibitors, com- 
petitively inhibited the MPTP metabolic activity of FMO, as 
well as MAO-B activity [3,4]. In addition to their inhibition of 
FMO, deprenyl and pargyline are excellent substrates for 
FMO. 
Table 1 
Kinetic parameters for the MAO-B inhibitors of FMO 
Inhibitors or K m (pM) Vm, x Ki a (pM) Refer- 
substrates (nmol/min/ ences 
mg protein 
of FMO) 
Deprenyl 14.3 313 14.0 This study 
Pargyline 11.6 385 9.0 This study 
MPTP 38.0 495 [6] 
The kinetic parameters were determined as described in section 2. 
aThe values for deprenyl or pargyline comprise the oxidative activity 
of FMO toward MPTP at pH 8.0 and 25°C. 
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Fig. 4. Effect of pargyline on the activity of FMO toward MPTP. The 
enzymatic reaction conditions were measured as described insection 2. 
The method of plotting was the same as described inthe legend to Fig. 
3, except hat deprenyl was replaced with pargyline. Open circles, 60 
tiM pargyline; closed triangles, 30tiM pargyline; open squares, without 
pargyline. 
The MPTP metabolic activity of FMO was strongly inhibited 
by deprenyl and pargyline. This indicates that the FMO may 
also contribute to the neuroprotective effect. 
This new finding suggests that, through inhibition of the 
activities of FMO and MAO-B, deprenyl may protect dopam- 
inergic nigral neurons of the substantia nigra from MPP+-in - 
duced neurotoxicity by induction of neurotrophic factors in 
astroglial cells [16], up-regulation of antioxidant defense n- 
zymes in the striatum [17], and/or suppression of the generation 
of cytotoxic OH and semiquinone radicals in iron-rich basal 
ganglia. 
The mammalian FMOs comprise a family of xenobiotic- 
metabolizing enzymes and they are found in most tissues of all 
mammalian species [18]. FMO catalyzes the oxygenation of 
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Fig. 5. Kinetic analysis for deprenyl of FMO. Double reciprocal plots 
of the initial velocity of the FMO reaction against various concentra- 
tions of deprenyl with a series of fixed concentrations of NADPH. The 
broken line shows the values extrapolated toan infinite concentration 
of deprenyl. The enzymatic assays were carried out as described in 
section 2. Open squares, 25 tiM NADPH; closed circles, 50 tiM 
NADPH; open triangles, 75 tM NADPH; open circles, 100 tM 
NADPH. 
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Fig. 6. Kinetic analysis for pargyline of FMO. The enzymatic reaction 
conditions were measured as described in section 2. The method of 
plotting was the same as described inthe legend to Fig. 5, except that 
deprenyl was replaced with pargyline. 
nucleophilic nitrogen, sulfur, phosphorous, and selenium 
atoms in a multitude of structurally diverse compounds [19]. In 
this study, deprenyl and pargyline were found to be typical 
tertiary amines, and they were metabolized strongly by porcine 
liver FMO, being converted quantitatively to N-oxides [20]. 
Judging from this and previous studies [3-7, 21], MPTP is 
metabolized by FMO [5,6], MAO-B [3], and cytochromes P-450 
(IA1, IIB1 and IID6). The metabolic pathways and enzymes 
related to MPTP are indicated in Fig. 7. This figure suggests 
that the metabolites of MPTP with FMO, MAO-B and P-450 
suppress the activities of NADH-CoQ reductase (Complex 1) 
and related enzymes, and ATP synthase (F~ • F0) in the mito- 
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Fig. 7. Metabolic pathways, and the enzymes for MPTP and its meta- 
bolites. The values in parentheses indicate Km (tiM). The Km value for 
MPTP of cytochrome P-450 IA1 was 0.87 tiM. 
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chondria of dopaminergic cells of the substantia nigra, and thus 
are the underlying cause of the ATP deficiency and subsequent 
dopaminegic cell death, and thereby produce Parkinson's dis- 
ease and Parkinsonism [22]. 
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